

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/022031-2023>

Tender

## **Process and Impact Evaluation**

Genomics England

F02: Contract notice

Notice identifier: 2023/S 000-022031

Procurement identifier (OCID): ocds-h6vhtk-03eb5f

Published 28 July 2023, 3:15pm

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

Genomics England

One Canada Square

London

E14 5AB

#### **Email**

[supplier.engagement@genomicsengland.co.uk](mailto:supplier.engagement@genomicsengland.co.uk)

#### **Telephone**

+44 2078825030

#### **Country**

United Kingdom

#### **Region code**

UKI - London

**Internet address(es)**

Main address

[www.genomicsengland.co.uk](http://www.genomicsengland.co.uk)

**I.3) Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://genomicsengland.bravosolution.co.uk>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://genomicsengland.bravosolution.co.uk>

Tenders or requests to participate must be submitted to the above-mentioned address

**I.4) Type of the contracting authority**

Body governed by public law

**I.5) Main activity**

Health

---

## **Section II: Object**

### **II.1) Scope of the procurement**

#### **II.1.1) Title**

Process and Impact Evaluation

Reference number

GEL-SR-534-22

#### **II.1.2) Main CPV code**

- 73210000 - Research consultancy services

#### **II.1.3) Type of contract**

Services

#### **II.1.4) Short description**

Genomics England's Generation Study aims to explore the benefits, challenges, and practicalities of offering whole genome sequencing to newborns, to accelerate diagnosis and access to treatment for rare genetic conditions. The programme funding was confirmed on 13 December 2022 with £105 million of funding to support it. Should it prove beneficial for participants and the wider health service, the study could pave the way for what would be the world's first national newborn screening programme to incorporate whole genome sequencing.

The outcome for this project is for Genomics England to work in partnership with an organisation or group of organisations with the specific expertise to deliver the Generation Study evaluation. The Generation Study will:

1. evaluate the scientific and clinical utility and validity, operational feasibility, and impact on the NHS of using Whole Genome Sequencing to screen for a large number of childhood-onset rare genetic conditions and provide ongoing patient support
2. understand how, with consent, newborns' genomic and health data could be used for research to enable new diagnostic discoveries and treatments to be developed
3. explore the potential risks, benefits, and broader implications of storing an individual's genome over their lifetime (e.g., potential for preventative steps, personalised risk-based screening in later life etc.)

Please note that this tender seeks a partner to evaluate the first of these three aims only.

#### **II.1.6) Information about lots**

This contract is divided into lots: No

### **II.2) Description**

#### **II.2.2) Additional CPV code(s)**

- 73000000 - Research and development services and related consultancy services

#### **II.2.3) Place of performance**

NUTS codes

- UKI - London

#### **II.2.4) Description of the procurement**

Two key components for which we require specific expertise in implementation science, behavioural science, health informatics and health economics are:

- Process Evaluation - will address research questions focusing specifically on whether the programme is acceptable and feasible. It will assess study delivery and processes to inform decision making for a possible future clinical service.

- Impact Evaluation - will address possible benefits and harms to:

- o Stakeholders – including participants, Health Care professionals, and the public

- o The System – including impact on existing newborn screening programmes and the impact on WGS for other patients as well as understanding comparative costs on the health care system.

- o Experiences and Attitudes – including participants, the public and 3rd sector organisations.

Genomics England will act as sponsor for the Generation Study and associated evaluation work. Genomics England is ultimately accountable for the research of which this evaluation forms part. The successful Tenderer will be responsible for design and delivery of all research related activities pursuant to the bid, including but not limited to the delivery of documents for the HRA and any other relevant regulatory bodies (where necessary).

#### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

#### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months

18

This contract is subject to renewal

Yes

Description of renewals

An extension option of up to 12 months will be available for this contract

#### **II.2.10) Information about variants**

Variants will be accepted: No

#### **II.2.11) Information about options**

Options: No

#### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

#### **II.2.14) Additional information**

Interested parties should register with Genomics England's e-tendering portal <https://genomicsengland.bravosolution.co.uk> and search for project\_857 to access all relevant documentation.

---

## **Section III. Legal, economic, financial and technical information**

### **III.1) Conditions for participation**

#### **III.1.2) Economic and financial standing**

Selection criteria as stated in the procurement documents

#### **III.1.3) Technical and professional ability**

Selection criteria as stated in the procurement documents

### **III.2) Conditions related to the contract**

#### **III.2.3) Information about staff responsible for the performance of the contract**

Obligation to indicate the names and professional qualifications of the staff assigned to performing the contract

---

## **Section IV. Procedure**

### **IV.1) Description**

#### **IV.1.1) Type of procedure**

Open procedure

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: No

### **IV.2) Administrative information**

#### **IV.2.2) Time limit for receipt of tenders or requests to participate**

Date

8 September 2023

Local time

12:00pm

#### **IV.2.4) Languages in which tenders or requests to participate may be submitted**

English

#### **IV.2.6) Minimum time frame during which the tenderer must maintain the tender**

Tender must be valid until: 1 November 2023

#### **IV.2.7) Conditions for opening of tenders**

Date

8 September 2023

Local time

12:00pm

---

## **Section VI. Complementary information**

### **VI.1) Information about recurrence**

This is a recurrent procurement: No

### **VI.2) Information about electronic workflows**

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

### **VI.3) Additional information**

Interested parties should register with Genomics England's e-tendering portal <https://genomicsengland.bravosolution.co.uk> and search for project\_857 to access all relevant documentation.

### **VI.4) Procedures for review**

#### **VI.4.1) Review body**

Public Procurement Review Service

London

Country

United Kingdom